Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F15%3A%230005042" target="_blank" >RIV/00023728:_____/15:#0005042 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/15:10318797 RIV/00216208:11510/15:10318797 RIV/00064165:_____/15:10318797
Result on the web
<a href="http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=16&SID=Y2RsBNomTQf3ElNG91B&page=1&doc=1" target="_blank" >http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=16&SID=Y2RsBNomTQf3ElNG91B&page=1&doc=1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/rheumatology/kev260" target="_blank" >10.1093/rheumatology/kev260</a>

Result language
angličtina
Original language name
Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease.
Original language description
The present study demonstrates overexpression of IL-35 in SSc skin, dermal fibroblasts and serum. TGF-β induces IL-35, which in turn activates resting fibroblasts and enhances the release of collagen, thereby contributing to aberrant TGF-β signalling in SSc. Increased serum IL-35 is associated with early, inflammatory stages of SSc
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—

Project
<a href="/en/project/NT12440" target="_blank" >NT12440: IL-35: a novel cytokine in systemic rheumatic diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)